Vyant Bio Overview
- Founded
-
1999
- Status
-
Public
- Employees
-
72
- Stock Symbol
-
VYNT
- Investments
-
5
- Share Price
-
$0.55
- (As of Wednesday Closing)
Vyant Bio General Information
Description
Vyant Bio Inc is an innovative biotechnology company reinventing drug discovery for complex neurodevelopmental and neurodegenerative disorders. Its Central nervous system (CNS) drug discovery platform combines human-derived organoid models of brain disease, scaled biology, and machine learning. The company's platform is designed to elucidate disease pathophysiology; formulate key therapeutic hypotheses; identify and validate drug targets, cellular assays, and biomarkers to guide candidate molecule selection; and guide clinical trial patient selection and trial design. The company derives prime revenue from the U.S.
Contact Information
Website
www.vyantbio.com
Formerly Known As
Cancer Genetics
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Pharmaceuticals
Other Industries
Drug Discovery
Stock Exchange
NAS
Primary Office
- 2 Executive Campus
- 2370 State Route 70 West, Suite 310
- Cherry Hill, NJ 08002
- United States
+1 (201) 000-0000
Vyant Bio Timeline
Vyant Bio Stock Performance
(As of Wednesday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $0.55 | $0.54 | $0.50 - $3.24 | $16.1M | 29.3M | 26.5K | -$1.69 |
Vyant Bio Financials Summary
|
In Thousands, USD |
TTM 30-Jun-2022 | FY 2021 31-Dec-2021 | FY 2020 31-Dec-2020 | FY 2019 31-Dec-2019 |
|---|---|---|---|---|
| EV | 12,580 | 16,933 | ||
| Revenue | 1,974 | 1,148 | 867 | 605 |
| EBITDA | (14,571) | (17,149) | (7,005) | (8,047) |
| Net Income | (44,275) | (40,859) | (8,650) | (8,956) |
| Total Assets | 26,811 | 37,636 | 4,049 | 4,193 |
| Total Debt | 2,191 | 1,197 | 7,952 | 1,384 |
Public Fundamental Data provided by Morningstar, Inc.
disclaimer
Vyant Bio Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Vyant Bio Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|
Vyant Bio Comparisons
Description
Primary
Industry
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Vyant Bio Inc is an innovative biotechnology company reinventing drug discovery for complex neurodevelopmental and neuro
Pharmaceuticals
Cherry Hill, NJ
72
As of 2021
000.00
000000000
000.00
000000
olore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliqu
000000000000000
Ardsley, NY
000
As of 0000
00000
0.00
0000-00-00
000000&0
000000
modo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugi
0000 000000000
San Diego, CA
00
As of 0000
00000
000000000
00000
Add Comparison
Vyant Bio Competitors (19)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Acorda Therapeutics | Formerly VC-backed | Ardsley, NY | 000 | 00000 | 000000&0 | |
| 0000000 00000000 | Formerly Angel backed | San Diego, CA | 00 | 00000 | 000000000 | 00000 |
| 000000 00000000 | Formerly VC-backed | Cambridge, MA | 000 | 00000 | 00000000000 | 00000 |
| 00000 000000000000 | Venture Capital-Backed | Didcot, United Kingdom | 0 | 00000 | 00000000000 | 00000 |
| 000000000 | Corporation | Epalinges, Switzerland | 00 | 0000000000 |
Vyant Bio Patents
Vyant Bio Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20160130665-A1 | Prognostic methods and systems for chronic lymphocytic leukemia | Inactive | 11-Nov-2014 | 0000000000 | |
| CA-2901543-A1 | Methods and tools for the diagnosis and prognosis of urogenital cancers | Inactive | 15-Feb-2013 | 0000000000 | |
| EP-2956551-A1 | Methods and tools for the diagnosis and prognosis of urogenital cancers | Inactive | 15-Feb-2013 | 0000000000 | |
| US-20140235458-A1 | Methods and tools for the diagnosis and prognosis of urogenital cancers | Inactive | 15-Feb-2013 | 0000000000 | |
| US-8865882-B2 | Methods for detecting human papilloma virus-associated cancers | Active | 08-Sep-2010 | C12Q1/708 | 00 |
Vyant Bio Executive Team (18)
Vyant Bio Board Members (11)
| Name | Representing | Role | Since |
|---|---|---|---|
| Geoffrey Harris Ph.D | Self | Board Member | 000 0000 |
| Howard McLeod Ph.D | Self | Board Member | 000 0000 |
| Joanna Horobin | Vyant Bio | Board Member | 000 0000 |
| John Roberts | Vyant Bio | Chief Executive Officer, President & Board Member | 000 0000 |
| Yung-Ping Yeh | Vyant Bio | Board Member & Executive | 000 0000 |
Vyant Bio Signals
Growth Rate
0.80%
Weekly
Growth
Growth
Weekly Growth
0.80%, 93rd %
-35.5%.
530%
Size Multiple
219x
Median
Size Multiple
219x, 100th %ile
0.00x
0.95x.
413Kx
Key Data Points
Twitter Followers
5.5k
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
Vyant Bio Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Vyant Bio Acquisitions (5)
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| 00000000 | 30-Mar-2021 | 0000000000 | 000.00 | Biotechnology | 0000 0000 |
| 000000000 | 15-Aug-2017 | 0000000000 | 00.00 | Other Pharmaceuticals and Biotechnology | 00000 000 |
| 00000000 0000 | 09-Oct-2015 | 0000000000 | 000.00 | Diagnostic Equipment | 000000 00 |
| 0000000 | 16-Jul-2014 | 0000000000 | 00.000 | Practice Management (Healthcare) | 00000 000 |
| Cancer Genetics India | 15-May-2014 | Merger/Acquisition | 00.00 | Laboratory Services (Healthcare) | 00000 000 |
Vyant Bio Subsidiaries (2)
| Company Name | Industry | Location | Founded |
|---|---|---|---|
| StemoniX | Biotechnology | Maple Grove, MN | 2014 |
| 000000000 | Other Pharmaceuticals and Biotechnology | Bundoora, Australia | 0000 |
Vyant Bio Exits (1)
| Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
|---|---|---|---|---|---|
| 000000 00000000 00 | 15-May-2014 | 000000000000000000 | 00.00 | Completed |
|